Stiefel Usha, Pultz Nicole J, Harmoinen Jaana, Koski Pertti, Lindevall Kai, Helfand Marion S, Donskey Curtis J
Division of Infectious Diseases, University Hospitals of Cleveland, Cleveland, Ohio 44106, USA.
J Infect Dis. 2003 Nov 15;188(10):1605-9. doi: 10.1086/379153. Epub 2003 Oct 23.
We hypothesized that orally administered, recombinant class A beta-lactamase would inactivate the portion of parenteral piperacillin excreted into the intestinal tract, preserving colonization resistance of mice against nosocomial pathogens. Subcutaneous piperacillin or piperacillin plus oral beta-lactamase were administered 24 and 12 h before orogastric inoculation of piperacillin-resistant pathogens. Oral administration of beta-lactamase reduced piperacillin-associated alteration of the indigenous microflora and prevented overgrowth of pathogens.
我们推测,口服重组A类β-内酰胺酶会使经肠道排泄的非肠道用哌拉西林失活,从而维持小鼠对医院病原体的定植抗性。在经口接种耐哌拉西林病原体之前24小时和12小时,分别皮下注射哌拉西林或哌拉西林加口服β-内酰胺酶。口服β-内酰胺酶可减少与哌拉西林相关的原生微生物群改变,并防止病原体过度生长。